<?xml version="1.0" encoding="UTF-8"?>
<p>Tuberculosis (TB) is the leading cause of death from infectious diseases, with 10 million new cases in 2017. About 1.7 billion people are estimated to have latent TB infection, and are at risk of developing active TB disease during their lifetime [
 <xref rid="B1-molecules-26-00475" ref-type="bibr">1</xref>]. The emergence of multidrug-resistant (MDR) and extremely drug-resistant (XDR) TB is primarily due to the improper use of the first-line anti-tubercular drug. The increased prevalence of such strains has become a major obstacle in the treatment of TB and also a serious financial burden on the health care sector. As a result, there is an urgent need for new cost-effective anti-TB drugs with new mechanisms of action and less chance of developing resistance [
 <xref rid="B2-molecules-26-00475" ref-type="bibr">2</xref>].
</p>
